Corrigendum: Safety of Semaglutide (Front. Endocrinol., (2021), 12, (645563), 10.3389/fendo.2021.645563)

Mark M. Smits; Daniël H. van Raalte

doi:https://doi.org/10.3389/fendo.2021.786732

Corrigendum: Safety of Semaglutide (Front. Endocrinol., (2021), 12, (645563), 10.3389/fendo.2021.645563)

Mark M. Smits, Daniël H. van Raalte

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Abstract

In the original article, there was a mistake in Table 2. Adverse effects and safety risks in phase 3 trials as published. Three values in the row for SUSTAIN 6, s.c semaglutide 1 mg were accidentally transposed to the incorrect column. The corrected Table 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original language	English
Article number	786732
Journal	Frontiers in Endocrinology
Volume	12
DOIs	https://doi.org/10.3389/fendo.2021.786732
Publication status	Published - 10 Nov 2021

Keywords

glucagon-like peptide-1 receptor agonist (GLP-1RA)
oral
safety
semaglutide
subcutaneous
type 2 diabetes

Access to Document

https://doi.org/10.3389/fendo.2021.786732

Cite this

@article{922311374c0241899531130be3e1cc2d,

title = "Corrigendum: Safety of Semaglutide (Front. Endocrinol., (2021), 12, (645563), 10.3389/fendo.2021.645563)",

abstract = "In the original article, there was a mistake in Table 2. Adverse effects and safety risks in phase 3 trials as published. Three values in the row for SUSTAIN 6, s.c semaglutide 1 mg were accidentally transposed to the incorrect column. The corrected Table 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",

keywords = "glucagon-like peptide-1 receptor agonist (GLP-1RA), oral, safety, semaglutide, subcutaneous, type 2 diabetes",

author = "Smits, {Mark M.} and {van Raalte}, {Dani{\"e}l H.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Smits and Van Raalte.",

year = "2021",

month = nov,

day = "10",

doi = "https://doi.org/10.3389/fendo.2021.786732",

language = "English",

volume = "12",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Corrigendum

T2 - Safety of Semaglutide (Front. Endocrinol., (2021), 12, (645563), 10.3389/fendo.2021.645563)

AU - Smits, Mark M.

AU - van Raalte, Daniël H.

PY - 2021/11/10

Y1 - 2021/11/10

N2 - In the original article, there was a mistake in Table 2. Adverse effects and safety risks in phase 3 trials as published. Three values in the row for SUSTAIN 6, s.c semaglutide 1 mg were accidentally transposed to the incorrect column. The corrected Table 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the original article, there was a mistake in Table 2. Adverse effects and safety risks in phase 3 trials as published. Three values in the row for SUSTAIN 6, s.c semaglutide 1 mg were accidentally transposed to the incorrect column. The corrected Table 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - glucagon-like peptide-1 receptor agonist (GLP-1RA)

KW - oral

KW - safety

KW - semaglutide

KW - subcutaneous

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85120743513&partnerID=8YFLogxK

U2 - https://doi.org/10.3389/fendo.2021.786732

DO - https://doi.org/10.3389/fendo.2021.786732

M3 - Comment/Letter to the editor

C2 - 34858353

SN - 1664-2392

VL - 12

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 786732

ER -

Corrigendum: Safety of Semaglutide (Front. Endocrinol., (2021), 12, (645563), 10.3389/fendo.2021.645563)

Abstract

Keywords

Access to Document

Other files and links

Cite this